Compare

Jenoptik AG/€JEN

1D1W1M3M6MYTD1Y5YMAX

About Jenoptik AG

Jenoptik AG is a global technology group specializing in photonics, with core operations in the Advanced Photonic Solutions and Smart Mobility Solutions divisions. The company offers products and services in areas such as semiconductor and electronics, life science and medical technology, and smart mobility. Founded in 1991, Jenoptik traces its origins to the Carl Zeiss AG company established in Jena, Germany, in 1846. Headquartered in Jena, the company employs approximately 4,600 people worldwide. Jenoptik's strategic focus includes photonic growth markets, aiming to develop into a globally positioned photonics company. (,)
Ticker
€JEN
Sector
Digital Hardware
Primary listing
XETRA
Employees
3,975
Headquarters
Jena, Germany
Website
www.jenoptik.com

Jenoptik AG Metrics

BasicAdvanced
€2.4B
26.83
€1.53
1.22
€0.40
0.98%

What the Analysts think about Jenoptik AG

Analyst ratings (Buy, Hold, Sell) for Jenoptik AG stock.
Analyst projections of the future price of Jenoptik AG stock.

Bulls say / Bears say

First-half order intake rose 53% to €723.4 million, lifting the order backlog to €824.8 million and book-to-bill to 1.44. That gives Jenoptik a much larger pipeline to convert into sales. (Jenoptik)
Reuters reported on 21 October that Jenoptik raised its full-year EBITDA-margin outlook on stronger semiconductor-equipment demand. That follows a 25.5% rise in first-half EBITDA and margin expansion to 19.7%. (Reuters, Jenoptik)
Smart Mobility Solutions revenue grew 10.7% in the first half, with growth across almost all regions. This provides a second source of momentum beyond semiconductor equipment. (Jenoptik)
Management warned that the exceptionally strong first-half order momentum may not continue, as it was partly driven by major orders and some customers ordered earlier than expected. If orders normalise, the current backlog build may prove difficult to repeat. (Jenoptik)
Metrology & Production Solutions revenue fell to €79.7 million from €92.0 million, with weakness across the unit linked partly to difficult automotive markets. The division remained slightly loss-making in the first half. (Jenoptik)
Biophotonics revenue declined 4.5% as medical-technology sales failed to match the prior year’s strong dental business. Its higher order intake included a multi-year large contract, so it has yet to translate into a broad-based sales recovery. (Jenoptik)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.

Jenoptik AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Jenoptik AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Jenoptik AG

AllEURUSDGBP
Funds
Fund name
Fund size
€JEN weighting
iShares TecDAX€EXS2
€645M1.55%
L&G ROBO Global Robotics and Automation$ROBO
$1.7B1.46%
L&G ROBO Global Robotics and Automation£ROBG
$1.7B1.46%
iShares MDAX€EXS3
€1.5B1.40%
iShares MDAX€EXID
€34M1.40%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.